{
    "nctId": "NCT00082810",
    "briefTitle": "Tipifarnib and Fulvestrant in Hormone Receptor-Positive Metastatic Breast Cancer",
    "officialTitle": "A Phase II Trial of Tipifarnib (R115777, Zarnestra\u2122) in Combination With Fulvestrant (Faslodex\u00ae) in Postmenopausal Hormone Receptor-Positive Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Estrogen Receptor-positive Breast Cancer, Recurrent Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 33,
    "primaryOutcomeMeasure": "Clinical Benefit Rate (CBR) (CR Rate, PR Rate, and SD)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Patients must have histologically or cytologically confirmed adenocarcinoma of the breast\n* Patients must be postmenopausal\n* Patients must have stage IV disease or inoperable locally advanced disease\n* Patients must have ER- and/or PR-positive disease as determined by their local pathology laboratory\n* Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as \\>= 20 mm with conventional techniques or as \\>= 10 mm with spiral CT scan; all sites of disease should be noted and followed\n* Prior hormonal therapy as adjuvant therapy and/or for metastatic disease is permitted; patients previously treated with two or more prior doses of fulvestrant are not eligible; patients who have received one prior dose of fulvestrant within 28 days are eligible so long as they meet other eligibility criteria\n* Patients must have ECOG performance status 0-2 (Karnofsky \\>= 60%)\n* Patients must have life expectancy of greater than 3 months\n* Leukocytes \\>= 3,000/uL\n* Absolute neutrophil count \\>= 1,500/uL\n* Platelets \\>= 100,000/uL\n* Total bilirubin =\\< 2 mg/dL\n* AST(SGOT)/ALT(SGPT) =\\< 2.5 x institutional upper limit of normal\n* Creatinine less than or equal to 1.5 times the institutional upper limits of normal\n* Patients must be disease-free of prior invasive malignancies for \\>= 5 years with the exception of: curatively-treated basal cell or squamous cell carcinoma of the skin, carcinoma in situ of the cervix\n* Patients must have the ability to understand and the willingness to sign a written informed consent document\n* Patients who have had previous therapy with farnesyltransferase inhibitor\n\nExclusion Criteria:\n\n* Patients who have had radiotherapy within 4 weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier; patients who have had prior chemotherapy for metastatic disease are not eligible; prior adjuvant or neoadjuvant chemotherapy is allowed\n* Patients may not be receiving any other investigational agents\n* History of allergic reactions attributed to compounds of similar chemical or biologic composition to tipifarnib (R115777, Zarnestra\u2122) or other agents used in the study (e.g., imidazoles, quinolones)\n* Presence of rapidly progressive, life-threatening metastases; this includes patients with extensive hepatic involvement (\\> 50% of the liver involved), symptomatic lymphangitic metastases, or brain or leptomeningeal involvement\n* Concomitant anticancer treatment with the following exceptions: (1) bisphosphonates for bone metastases, (2) a GnRH analog is permitted if the patient had progressive disease on a GnRH analog plus a SERM or an AI; the GnRH analog may continue but the SERM or AI must be discontinued\n* Grade 2 or more peripheral neuropathy\n* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements\n* HIV-positive patients receiving combination anti-retroviral therapy are excluded from the study because of possible pharmacokinetic interactions with tipifarnib or other agents administered during the study.; appropriate studies will be undertaken in patients receiving combination anti-retroviral therapy when indicated",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}